Janney Montgomery Scott
NVCR icon

Janney Montgomery Scott’s NovoCure NVCR Stock Holding History

Janney Montgomery Scott’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-37,861
Closed -$5M – 2285
2021
Q1 		$5M Sell
37,861
-9,642
-20% -$1.53M 0.02% 557
2020
Q4 		$8.22M Buy
+47,503
New +$6.5M 0.04% 378
2020
Q1 		– Sell
-10,168
Closed -$857K – 2018
2019
Q4 		$857K Sell
10,168
-2,218
-18% -$179K 0.01% 1159
2019
Q3 		$926K Sell
12,386
-6,911
-36% -$553K 0.01% 1081
2019
Q2 		$1.22M Sell
19,297
-86
-0.4% -$4.36K 0.01% 947
2019
Q1 		$934K Sell
19,383
-334
-2% -$16.1K 0.01% 1065
2018
Q4 		$660K Sell
19,717
-1,076
-5% -$39.3K 0.01% 1139
2018
Q3 		$1.09M Buy
20,793
+246
+1% +$9.79K 0.01% 977
2018
Q2 		$643K Buy
+20,547
New +$572K 0.01% 1251

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janney Montgomery Scott's NVCR Position: Q2 2021 in Review

Janney Montgomery Scott sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 37,861 shares — an estimated $5M sold.

Janney Montgomery Scott first reported a position in NVCR in Q2 2018 and held it in 9 quarters. The position peaked at $8.22M in Q4 2020. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

  • Janney Montgomery Scott reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
  • Janney Montgomery Scott sold 37,861 NovoCure shares in Q2 2021, an estimated $5M.
  • Janney Montgomery Scott first reported a position in NovoCure in Q2 2018 and held it in 9 quarters.
  • Janney Montgomery Scott's NovoCure position peaked at $8.22M in Q4 2020.
  • 361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Janney Montgomery Scott's 13F filing for Q2 2021, filed 26 Jul 2021.